With a lack of randomized data, we plan on leveraging the population-based Stockholm Prostate Cancer Diagnostics Register from 2007 to 2023, to explore the effect of PSA-based screening on all-cause and prostate cancer–specific mortality. Here, KLK3 is linked to prostate cancer.